NewsRx

Search our medical news database

Diabetes Therapy

Private company to produce iron-binding drugs for use in U.S. clinical studies

Published in Obesity and Diabetes Week, May 2nd, 2005

Hemosol Corp. has negotiated an agreement with Biomedical Frontiers Incorporated (BMF), a private biopharmaceutical company located in Minneapolis, Minnesota, under which Hemosol will produce two separate iron-binding drugs (40SD02 and 25SD04).

These injectable drug formulations will be used for pre-clinical and clinical studies for treatment of iron poisoning, iron overload, and diabetic complications. Production is scheduled to begin in the second quarter of 2005. Revenue from the agreement governing the BMF relationship is expected to contribute to modestly reducing Hemosol's burn rate in 2005.

"The key benefit to Hemosol from this agreement is...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook